Elvina Almuradova/LinkedIn
Jun 2, 2025, 21:29
Elvina Almuradova: The SERENA-6 Trial Introduces a New Standard in ESR1-mutant ER+/HER2- Advanced Breast Cancer
Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology, shared a post on LinkedIn:
“ASCO25 — The SERENA-6 trial introduces a new standard in ESR1-mutant ER+/HER2- advanced breast cancer.
Camizestrant, a next-gen oral SERD, significantly prolonged PFS (16.0 vs 9.2 months) when switched at molecular progression (via ctDNA), before radiologic progression.
Improved quality of life
Low discontinuation rate
Better tolerated than AIs
A compelling move toward molecular response–guided therapy in first-line ER+ MBC.”
Read OncoDaily’s Special Articles about ASCO 2025:
15 Posts Not to Miss from the 1st Day of ASCO 2025
15 Posts Not to Miss from the 2nd Day of ASCO 2025
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 7, 2025, 17:41
Jun 7, 2025, 16:47
Jun 7, 2025, 16:40
Jun 7, 2025, 16:30
Jun 7, 2025, 16:07
Jun 7, 2025, 15:49